{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T15:45:56Z","timestamp":1768405556851,"version":"3.49.0"},"reference-count":95,"publisher":"Informa UK Limited","issue":"5","funder":[{"name":"the German Academic Scholarship Foundation"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"published-print":{"date-parts":[[2023,5,28]]},"DOI":"10.1080\/14737167.2023.2193690","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T16:32:00Z","timestamp":1679502720000},"page":"469-482","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Review of economic modeling evidence from NICE appraisals of rare disease treatments for spinal muscular atrophy"],"prefix":"10.1080","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8259-0774","authenticated-orcid":false,"given":"Lea","family":"Wiedmann","sequence":"first","affiliation":[{"name":"Department of Health Services Research and Policy, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6442-0440","authenticated-orcid":false,"given":"John","family":"Cairns","sequence":"additional","affiliation":[{"name":"Department of Health Services Research and Policy, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"key":"#cr-split#-cit0001.1","unstructured":"Goodman CS . HTA 101: II. fundamental concepts. 2014 [updated 2019 Nov 21"},{"key":"#cr-split#-cit0001.2","unstructured":"Cited 2022 Nov 21]. Available from: https:\/\/www.nlm.nih.gov\/nichsr\/hta101\/ta10103.html"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462308080343"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2017.03.009"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30006-3"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-6-71"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60921-6"},{"key":"cit0007","unstructured":"European Commission (EC). Rare Diseases - A major unmet medical need. Brussels: Publications Office of the EU; 2017 Nov 07 [cited 2023 Mar 17]. Available from: https:\/\/op.europa.eu\/en\/publication-detail\/-\/publication\/c2ba4fd4-ae31-11e7-837e-01aa75ed71a1"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462307051550"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-020-05805-2"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-7-74"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-020-00624-2"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-021-01105-7"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1586\/erp.11.95"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1177\/2399202618810121"},{"key":"cit0015","unstructured":"NHS England strikes deal on life-saving gene-therapy drug that can help babies with rare genetic disease move and walk. 2021 Mar 8 [cited 2022 Sep 26]. Available from: https:\/\/www.england.nhs.uk\/2021\/03\/nhs-england-strikes-deal-on-life-saving-gene-therapy-drug-that-can-help-babies-with-rare-genetic-disease-move-and-walk\/"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-020-00493-w"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462320000665"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-021-01115-5"},{"key":"cit0019","unstructured":"Institute for Clinical and Economic Review (ICER). Spinraza\u00ae and Zolgensma\u00ae for spinal muscular atrophy: effectiveness and value. 2019 Apr 3 [cited 2023Mar17] . Available from: https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_SMA_Final_Evidence_Report_110220.pdf"},{"key":"cit0020","unstructured":"National Institute for Health and Care Excellence (NICE). Nusinersen for treating spinal muscular atrophy [TA588]. 2019 Jul 24 [cited 2022 Sep 26]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta588\/history"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9072222"},{"key":"cit0022","unstructured":"National Institute for Health and Care Excellence (NICE). Onasemnogene abeparvovec for treating spinal muscular atrophy [HST15]. 2021 Jul 7 [cited 2022 Sep 26]. Available from: https:\/\/www.nice.org.uk\/guidance\/hst15\/history"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1186\/s42466-021-00162-9"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00741"},{"key":"cit0025","unstructured":"National Institute for Health and Care Excellence (NICE).Onasemnogene abeparvovec for treating pre-symptomatic spinal muscular atrophy (partial review of HST15). Final draft guidance.2023 Mar 16 [cited 2023 Mar 17]. Available from: https:\/\/www.nice.org.uk\/guidance\/gid-hst10053\/documents\/final-evaluation-determination-document"},{"key":"cit0026","unstructured":"National Institute for Health and Care Excellence (NICE). Risdiplam for treating spinal muscular atrophy [TA755]. 2021 Dec 16 [cited 2022 Sep 26]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta755\/history"},{"key":"cit0027","unstructured":"National Institute for Health and Care Excellence (NICE). Final appraisal document: nusinersen for treating spinal muscular atrophy [TA588]. 2019 Jul [cited 2022 Sep 26] . Available from: https:\/\/www.nice.org.uk\/guidance\/ta588\/documents\/final-appraisal-determination-document-2"},{"key":"cit0028","unstructured":"ISPOR. Delivering evidence-based access in rare diseases: the challenges in SMA. 2022 Apr 05 [cited 2022 Sep 26]. Available from: https:\/\/www.ispor.org\/conferences-education\/education-training\/webinars\/webinar\/delivering-evidence-based-access-in-rare-diseases-the-challenges-in-sma"},{"key":"#cr-split#-cit0029.1","unstructured":"European Commission (EC) [Internet]. Union Register of medicinal products for human use. European Commission procedures: Zolgensma. [updated 2022 Sep 12"},{"key":"#cr-split#-cit0029.2","unstructured":"cited 2022 Sep 26]. Available from: https:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/h1443.htm"},{"key":"#cr-split#-cit0030.1","unstructured":"European Commission (EC) [Internet]. Union Register of medicinal products for human use. European Commission procedures: Evrysdi. [updated 2022 Sep 26"},{"key":"#cr-split#-cit0030.2","unstructured":"cited 2022 Sep 26]. Available from: https:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/h1531.htm"},{"key":"#cr-split#-cit0031.1","unstructured":"European Commission (EC) [Internet]. Union Register of medicinal products for human use. European Commission procedures: Spinraza. [updated 2022 Apr 4"},{"key":"#cr-split#-cit0031.2","unstructured":"cited 2022 Sep 26]. Available from: https:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/h1188.htm"},{"key":"cit0032","unstructured":"National Institute for Health and Care Excellence (NICE). Final appraisal document: risdiplam for treating spinal muscular atrophy [TA755]. 2021 Nov [cited 2022 Sep 26] . Available from: https:\/\/www.nice.org.uk\/guidance\/ta755\/documents\/final-appraisal-determination-document-6"},{"key":"cit0033","unstructured":"National Institute for Health and Care Excellence (NICE). Final evaluation document: onasemnogene abeparvovec for treating spinal muscular atrophy [HST15]. 2021 May [cited 2022 Sep 26] . Available from: https:\/\/www.nice.org.uk\/guidance\/hst15\/documents\/final-evaluation-determination-document"},{"key":"cit0034","unstructured":"Novartis Gene Therapies. Highly specialised technology evaluation Onasemnogene abeparvovec for treating pre-symptomatic spinal muscular atrophy (MAA partial review of HST 15) [ID4051]. Document B Company evidence submission. 2022 Aug 11 [cited 2022 Mar 17]. Available from https:\/\/www.nice.org.uk\/guidance\/gid-hst10053\/documents\/committee-papers"},{"key":"cit0035","unstructured":"Novartis Gene Therapies. Highly specialised technologies evaluation programme. INTERIM. ZOLGENSMA\u00ae (onasemnogene abeparvovec) for treating spinal muscular atrophy type 1 [ID1473]. Specification for company submission of evidence: supplementary Appendix. 2020 May 1 [cited 2022 Sep 26] . Available from: https:\/\/www.nice.org.uk\/guidance\/hst15\/documents\/committee-papers"},{"key":"cit0036","unstructured":"Roche Products. Single technology appraisal. ID1631: risdiplam for treating spinal muscular atrophy in children and adults. Document B: company evidence submission. 2020 Oct 30 cited 2022 Sep 26] . Available from: https:\/\/www.nice.org.uk\/guidance\/ta755\/documents\/committee-papers"},{"key":"cit0037","unstructured":"Biogen International GmbH. Single technology appraisal: nusinersen for treating spinal muscular atrophy [ID1069]. Document B: company evidence submission. 2018 Mar 15 cited 2022 Sep 26] . Available from: https:\/\/www.nice.org.uk\/guidance\/ta588\/documents\/committee-papers"},{"key":"cit0038","unstructured":"Tappenden P, Hock E Nusinersen for treating spinal muscular atrophy: a single technology appraisal. Addendum 2: ERG comments on company\u2019s revised models and additional economic analyses. Sheffield: School of Health and Related Research (ScHARR), The University of Sheffield; 2019 Feb 22 [cited 2022 Sep 26] . Available from: https:\/\/www.nice.org.uk\/guidance\/ta588\/documents\/committee-papers-4"},{"key":"cit0039","unstructured":"Products R. Risdiplam for treating spinal muscular atrophy in children and adults [ID1631]. Roche technical engagement response form. 2021 Mar 10 [cited 2022 Sep 26] . Available from: https:\/\/www.nice.org.uk\/guidance\/ta755\/documents\/committee-papers"},{"key":"cit0040","unstructured":"Tappenden P, Hock E, Hamilton J, et al. Nusinersen for treating spinal muscular atrophy: a Single Technology Appraisal. Addendum - ERG commentary on company\u2019s ACD response . Sheffield: School of Health and Related Research (ScHARR), The University of Sheffield [cited 2022 Sep 22]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta588\/documents\/committee-papers-4"},{"key":"cit0041","unstructured":"Roche Products. Risdiplam for treating spinal muscular atrophy in children and adults [ID1631]. Roche ACD stakeholder comments. 2021 Jun cited 2022 Sep 26] . Available from: https:\/\/www.nice.org.uk\/guidance\/ta755\/documents\/committee-papers-3"},{"key":"cit0042","unstructured":"Tappenden P, Navega Biz A, Hock E Risdiplam for treating spinal muscular atrophy: a single technology appraisal. Addendum: ERG\u2019s comments on the company\u2019s ACD response. Sheffield: School of Health and Related Research (ScHARR), The University of Sheffield; 2021 Jul 6 [cited 2022 Sep 26] . Available from: https:\/\/www.nice.org.uk\/guidance\/ta755\/documents\/committee-papers-3"},{"key":"cit0043","unstructured":"Tappenden P, Hock E, Stevens J, et al. Risdiplam for treating spinal muscular atrophy: a single technology appraisal. Sheffield: School of Health and Related Research (ScHARR), The University of Sheffield; 2021 Feb 3 [cited 2022 Sep 26] . Available from: https:\/\/www.nice.org.uk\/guidance\/ta755\/documents\/committee-papers"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-014-0153-y"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.08.911"},{"key":"cit0046","unstructured":"Biogen International GmbH. Nusinersen (SPINRAZA\u00ae) for the treatment of 5q spinal muscular atrophy. supplementary appendix 2: cost-effectiveness model revisions and updated results [cited 2022 Sep 26]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta588\/documents\/committee-papers-4"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0695-0"},{"key":"cit0048","unstructured":"Novartis Gene Therapies. Highly specialised technologies evaluation programme. INTERIM. ZOLGENSMA\u00ae (onasemnogene abeparvovec) for treating spinal muscular atrophy type 1 [ID1473]. Specification for company submission of evidence: supplementary Appendix. 2019 Aug 19 [cited 2022 Sep 26] . Available from: https:\/\/www.nice.org.uk\/guidance\/hst15\/documents\/committee-papers"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S214084"},{"key":"cit0050","unstructured":"Tappenden P, Hock E, Stevens J, et al. Risdiplam for treating spinal muscular atrophy: a single technology appraisal. Addendum: ERG comments on company\u2019s technical engagement response. Sheffield: School of Health and Related Research (ScHARR), The University of Sheffield; 2021 Mar 22 [cited 2022 Sep 26] . Available from: https:\/\/www.nice.org.uk\/guidance\/ta755\/documents\/committee-papers"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.11.015"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-genom-102319-103602"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21093297"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.05.011"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-020-00413-4"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2017.52"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-021-01095-6"},{"key":"cit0058","unstructured":"Managed Access Oversight Committee (MAOC). Recommendations from the managed access oversight committee: nusinersen for treating spinal muscular atrophy [NICE Technology Appraisal 588] Managed Access Agreement. Clinical eligibility criteria evidence review. 2021 Mar 8 [cited 2022 Sep 26] . Available from: https:\/\/www.nice.org.uk\/guidance\/ta588\/evidence\/managed-access-oversight-committee-maoc-recommendation-report-pdf-9138885233"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-022-00369-9"},{"key":"cit0060","unstructured":"National Institute for Health and Care Excellence (NICE). Real-world evidence framework. 2022 Jun 23 [cited 2022 Sep 26]. Available from: https:\/\/www.nice.org.uk\/corporate\/ecd9\/chapter\/overview"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2014.12.016"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-02061-3"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-021-01387-w"},{"key":"cit0064","unstructured":"National Institute for Health and Care Excellence (NICE). NICE health technology evaluations: the manual. 2022 Jan 31 [cited 2022Sep 26] . Available from: https:\/\/www.nice.org.uk\/process\/pmg36\/resources\/nice-health-technology-evaluations-the-manual-pdf-72286779244741"},{"key":"#cr-split#-cit0065.1","unstructured":"EuroQol [Internet]. EQ-5D-Y (Youth) | about. [updated 2021 Nov 30"},{"key":"#cr-split#-cit0065.2","unstructured":"cited 2022 Sep 26]. Available from: https:\/\/euroqol.org\/eq-5d-instruments\/eq-5d-y-about\/"},{"key":"#cr-split#-cit0066.1","unstructured":"EuroQol [Internet]. Status of EQ-5D-Y valuation using standardized valuation methodology. 2022 [updated 2022 Mar 07"},{"key":"#cr-split#-cit0066.2","unstructured":"cited 2022 Sep 30]. Available from: https:\/\/euroqol.org\/wp-content\/uploads\/2021\/01\/Overview-of-youth-valuation-studies_worldmap-7mar2022.pdf"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-017-0550-0"},{"key":"cit0068","unstructured":"Pennington B, Wong R Modelling carer health-related quality of life in NICE technology appraisals and highly specialised technologies. 2019 Apr 3 [cited 2023 Mar17] . Available from: https:\/\/www.sheffield.ac.uk\/nice-dsu\/methods-development"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.05.017"},{"key":"cit0070","unstructured":"UK National Screening Committee. Antenatal and newborn screening programme: SMA [cited 2022 Sep 26]. cited: https:\/\/view-health-screening-recommendations.service.gov.uk\/sma\/"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2012-2278"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25101"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100346"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010540"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(96)00284-5"},{"key":"cit0076","unstructured":"Biogen International GmbH. [ID1069] Nusinersen (SPINRAZA\u00ae) for the treatment of 5q spinal muscular atrophy. Cost-effectiveness model revisions and updated results \u2013 addendum 1. 2019 [cited 2022 Sep 26]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta588\/documents\/committee-papers-4"},{"key":"cit0077","unstructured":"Edwards SJ, Barton S, Jhita T, et al. Onasemnogene abeparvovec for treating spinal muscular atrophy: a highly specialised technology appraisal. London: BMJ Technology Assessment Group; 2020 Aug 28 [cited 2022 Sep 26] . Available from: https:\/\/www.nice.org.uk\/guidance\/hst15\/documents\/committee-papers"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2524.2006.00639.x"},{"key":"cit0079","unstructured":"Tappenden P, Hamilton J, Kaltenthaler E, et al. Nusinersen for treating spinal muscular atrophy: a single technology appraisal. Sheffield: School of Health and Related Research (ScHARR), The University of Sheffield; 2018 May 30 [cited 2022 Sep26] . Available from: https:\/\/www.nice.org.uk\/guidance\/ta588\/documents\/committee-papers"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.08.1962"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2010.00700.x"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1111\/j.1741-3729.2010.00601.x"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-020-00234-8"},{"key":"cit0084","unstructured":"National Institute for Health and Care Excellence (NICE). Nusinersen for treating spinal muscular atrophy [TA588]. 2019Jul 24 [cited 2023 Mar 17]. Available from https:\/\/www.nice.org.uk\/guidance\/ta588\/resources"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-022-01164-4"},{"key":"cit0086","unstructured":"First UK pilot study of newborn screening for spinal muscular atrophy launched in Oxford. 2022 Mar 11 [cited 2022 Sep 26]. Available from: https:\/\/www.ox.ac.uk\/news\/2022-03-11-first-uk-pilot-study-newborn-screening-spinal-muscular-atrophy-launched-oxford"},{"key":"cit0087","unstructured":"NHS England. Innovative Medicines Fund. 2022 [cited 2022 Sep 30]. Available from: https:\/\/www.england.nhs.uk\/medicines-2\/innovative-medicines-fund\/#will-cancer-medicines-be-disadvantaged-by-the-creation-of-the-innovative-medicines-fund"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.3390\/cells11030417"},{"key":"cit0089","unstructured":"ClinicalTrials.gov [Internet]. Identifier NCT05156320, efficacy and safety of apitegromab in patients with later-onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam (SAPPHIRE). Bethesda (MD): National Library of Medicine (US). 2021 Dec 14 [cited 2022 Sep 26]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05156320?term=sapphire+scholar+rock&draw=2&rank=1"}],"container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737167.2023.2193690","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T17:42:47Z","timestamp":1683135767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737167.2023.2193690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,5]]},"references-count":95,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5,28]]}},"alternative-id":["10.1080\/14737167.2023.2193690"],"URL":"https:\/\/doi.org\/10.1080\/14737167.2023.2193690","relation":{},"ISSN":["1473-7167","1744-8379"],"issn-type":[{"value":"1473-7167","type":"print"},{"value":"1744-8379","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-10-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}